These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 37416756)

  • 21. Defining Exposure Predictors of Meropenem That Are Associated with Improved Survival for Severe Bacterial Infection: A Preclinical PK/PD Study in Sepsis Rat Model.
    Wang Y; Liu L; Wu Q; Yin Q; Xie F
    Antibiotics (Basel); 2022 Nov; 11(11):. PubMed ID: 36421304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.
    Nielsen EI; Cars O; Friberg LE
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4619-30. PubMed ID: 21807983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
    Wong G; Briscoe S; McWhinney B; Ally M; Ungerer J; Lipman J; Roberts JA
    J Antimicrob Chemother; 2018 Nov; 73(11):3087-3094. PubMed ID: 30137377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A guide to therapeutic drug monitoring of β-lactam antibiotics.
    Fratoni AJ; Nicolau DP; Kuti JL
    Pharmacotherapy; 2021 Feb; 41(2):220-233. PubMed ID: 33480024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low attainment to PK/PD-targets for β-lactams in a multi-center study on the first 72 h of treatment in ICU patients.
    Smekal AK; Furebring M; Eliasson E; Lipcsey M
    Sci Rep; 2022 Dec; 12(1):21891. PubMed ID: 36535989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.
    Sinnollareddy MG; Roberts MS; Lipman J; Roberts JA
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):489-96. PubMed ID: 22519600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents.
    Sato N; Suzuki H; Hayashi H; Shibasaki S; Sugano T; Maebashi K; Kurosawa T; Shiomi M; Ogata H
    Jpn J Antibiot; 2008 Oct; 61(5):314-38. PubMed ID: 19260351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limitations of Antibiotic MIC-Based PK-PD Metrics: Looking Back to Move Forward.
    Landersdorfer CB; Nation RL
    Front Pharmacol; 2021; 12():770518. PubMed ID: 34776982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling.
    Delattre IK; Hites M; Laterre PF; Dugernier T; Spapen H; Wallemacq PE; Jacobs F; Taccone FS
    Int J Antimicrob Agents; 2020 Oct; 56(4):106113. PubMed ID: 32721604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of β-Lactam Dosing Regimens in Neonatal Infections: Continuous and Extended Administration versus Intermittent Administration.
    Leegwater E; Wewerinke L; de Grauw AM; van Veen M; Storm BN; Kruizinga MD
    Clin Pharmacokinet; 2023 May; 62(5):715-724. PubMed ID: 36972008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
    Chen M; Buurma V; Shah M; Fahim G
    Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria.
    Kothekar AT; Divatia JV; Myatra SN; Patil A; Nookala Krishnamurthy M; Maheshwarappa HM; Siddiqui SS; Gurjar M; Biswas S; Gota V
    Ann Intensive Care; 2020 Jan; 10(1):4. PubMed ID: 31925610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever.
    Maarbjerg SF; Thorsted A; Friberg LE; Nielsen EI; Wang M; Schrøder H; Albertsen BK
    Cancer Rep (Hoboken); 2022 Oct; 5(10):e1585. PubMed ID: 34796702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How predictive is PK/PD for antibacterial agents?
    Frimodt-Møller N
    Int J Antimicrob Agents; 2002 Apr; 19(4):333-9. PubMed ID: 11978504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meropenem for the Pharmacological Treatment of Severe Infections in Critically Ill Pediatric Patients: Breakthrough Standard Treatment Strategies Based on PK/PD.
    He X; Liu X; Gong X; Wang L; Chen F
    Curr Drug Metab; 2023; 24(1):5-15. PubMed ID: 36974414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
    Landmesser KB; Clark JA; Burgess DS
    J Clin Pharmacol; 2022 Apr; 62(4):479-485. PubMed ID: 34614542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bacterial sepsis : Diagnostics and calculated antibiotic therapy].
    Richter DC; Heininger A; Brenner T; Hochreiter M; Bernhard M; Briegel J; Dubler S; Grabein B; Hecker A; Krüger WA; Mayer K; Pletz MW; Störzinger D; Pinder N; Hoppe-Tichy T; Weiterer S; Zimmermann S; Brinkmann A; Weigand MA; Lichtenstern C
    Anaesthesist; 2017 Oct; 66(10):737-761. PubMed ID: 28980026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy.
    Ngougni Pokem P; Vanneste D; Schouwenburg S; Abdulla A; Gijsen M; Dhont E; Van der Linden D; Spriet I; De Cock P; Koch B; Van Bambeke F; Wijnant GJ
    Expert Opin Drug Metab Toxicol; 2024 Aug; 20(8):787-804. PubMed ID: 39078238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.